A Phase 1 Study of OSI-906 in Combination with AZD6244 Hydrogen Sulfate in Patients with Ras/Raf/GNAQ Mutated Advanced Cancer Refractory to Standard Therapy

Trial Profile

A Phase 1 Study of OSI-906 in Combination with AZD6244 Hydrogen Sulfate in Patients with Ras/Raf/GNAQ Mutated Advanced Cancer Refractory to Standard Therapy

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2014

At a glance

  • Drugs Linsitinib (Primary) ; Selumetinib (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 08 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top